Response to letter: “Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule” by Suzuki et al

•Two <25% responders achieved a > 25% response after the switch to fremanezumab.•Accompanying symptoms improved from baseline with both CGRP monoclonal antibodies.•Alopecia was alleviated after switching, while constipation persisted.

Saved in:
Bibliographic Details
Published inJournal of the neurological sciences Vol. 455; p. 122785
Main Authors Ihara, Keiko, Ohtani, Seiya, Watanabe, Narumi, Takahashi, Nobuyuki, Hori, Satoko, Nakahara, Jin, Takizawa, Tsubasa
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 15.12.2023
Subjects
Anti-calcitonin gene-related peptide monoclonal antibodies
Fremanezumab
Galcanezumab
Migraine
Neurology
Switch
Fremanezumab
Switch
MMD
Migraine
anti-CGRP mAbs
Anti-calcitonin gene-related peptide monoclonal antibodies
Galcanezumab
monthly migraine days
Online AccessGet full text

Cover

More Information
Summary:•Two <25% responders achieved a > 25% response after the switch to fremanezumab.•Accompanying symptoms improved from baseline with both CGRP monoclonal antibodies.•Alopecia was alleviated after switching, while constipation persisted.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ObjectType-Commentary-2
content type line 23
ISSN:0022-510X
1878-5883
1878-5883
DOI:10.1016/j.jns.2023.122785